Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma [0.03%]
血管内皮生长因子靶向治疗透明细胞肾细胞癌的基因组改变及临床疗效研究
M I Carlo,B Manley,S Patil et al.
M I Carlo et al.
Background: Mutations in VHL, PBRM1, SETD2, BAP1, and KDM5C are common in clear cell renal cell carcinoma (ccRCC), and presence of certain mutations has been associated with outcomes in patients with non-metastatic disease. Limited informat...
Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC) [0.03%]
靶向治疗时代转移性肾嫌色细胞癌的预后：国际转移性肾细胞癌数据库联盟(IMDC)的结果分析
Steven M Yip,Jose M Ruiz Morales,Frede Donskov et al.
Steven M Yip et al.
Background: Treatment outcomes are poorly characterized in patients with metastatic chromophobe renal cell cancer (chrRCC), a subtype of renal cell carcinoma. Objective: This retrospective series aims to determine metastatic chrRCC treatmen...
Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path Forward [0.03%]
非转移性肾细胞癌围手术期治疗范式的转变-可能的前进道路
L C Harshman,C G Drake,N B Haas et al.
L C Harshman et al.
In 2017, there is no adjuvant systemic therapy proven to increase overall survival in non-metastatic renal cell carcinoma (RCC). The anti-PD-1 antibody nivolumab improves overall survival in metastatic treatment refractory RCC and is genera...
Manuel Caitano Maia,Nazli Dizman,Meghan Salgia et al.
Manuel Caitano Maia et al.
The influx of multiple novel therapeutic options in the mRCC field has brought a challenge for treatment sequencing in this disease. In the past few years, cabozantinib, nivolumab and the combination of lenvatinib and everolimus have been a...
Molecular Classification of Renal Cell Carcinoma and Its Implication in Future Clinical Practice [0.03%]
肾细胞癌的分子分型及其对未来临床实践的影响
Jozefina Casuscelli,Yann-Alexandre Vano,Wolf Herve Fridman et al.
Jozefina Casuscelli et al.
Renal cell carcinoma (RCC) encompasses a wide spectrum of morphologically and molecularly distinct (>10) cancer subtypes originated from the kidney epithelium. Metastatic RCC (mRCC) is lethal and refractory to conventional chemotherapeutic ...
Primo N Lara Jr,Peter F A Mulders
Primo N Lara Jr
Systematic Review: ClearCode 34 - A Validated Prognostic Signature in Clear Cell Renal Cell Carcinoma (ccRCC) [0.03%]
系统综述：ClearCode 34在透明细胞肾细胞癌中的预后价值
Pooja Ghatalia,W Kimryn Rathmell
Pooja Ghatalia
The standard of care of patients with localized clear cell RCC (ccRCC) is observation after nephrectomy. However, a third of these patients have local or distant recurrence. Along with basic clinical and pathologic variables like stage, nec...